퀘르세틴 관련 급성 기관지염
B 근거 적어도 하나의 무작위 시험이 이를 지지하며, 대체로 일관된 결과를 보입니다.Meta-analyses associate NAC supplementation with lower inflammatory markers and improved oxygenation in respiratory patients. Its well-established mucolytic properties support airway clearance in acute bronchitis. NAC is an FDA-approved mucolytic agent with a long safety record.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'immunecited.com';
const params = 'ingredient\u003Dnac\u0026condition\u003Dacute\u002Dbronchitis';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
결론
Meta-analyses associate NAC supplementation with lower inflammatory markers and improved oxygenation in respiratory patients. Its well-established mucolytic properties support airway clearance in acute bronchitis. NAC is an FDA-approved mucolytic agent with a long safety record.
Key Study Findings
Review
N-acetylcysteine in paediatrics: a review of efficacy, safety and dosing strategies in respiratory care.
Dose: 20 mg/kg/day acute; 200 mg TID chronic
vs: None
Outcome: Efficacy in pediatric respiratory diseases
효과: None
None
대상 집단: Children with acute/chronic respiratory diseases
Other
n=270
8 weeks
N-acetyl-L-cysteine and lauric acid; effective antioxidant and antimicrobial feed additives for juvenile Pacific white shrimp …
Dose: 0.2% supplementation
vs: Control diet at LSD and HSD
Outcome: Growth, immune and antioxidant response in shrimp
효과: None
None
대상 집단: Pacific white shrimp (L. vannamei) at high stocking density
In Vitro
Improving in vitro induction efficiency of human primordial germ cell-like cells using N2B27 or NAC-based …
Dose: None
vs: GK15 induction without NAC
Outcome: hPGCLC induction efficiency
효과: None
None
대상 집단: Human iPSCs (in vitro)
Review
Cautious Hope for Cannabidiol (CBD) in Rheumatology Care.
Dose: Cannabidiol (CBD)
vs: None
Outcome: Pain and inflammation in rheumatic diseases
효과: None
None
대상 집단: Patients with rheumatic diseases
Randomized Controlled Trial
n=333
1.0 weeks
Double-blind
Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion.
Dose: 600 mg
vs: placebo and ambroxol
Outcome: Sputum viscosity and expectoration difficulty
효과: None
p<0.001
대상 집단: Patients with respiratory disease and abnormal mucus
animal study (controlled experiment)
n=120
3 weeks
Effects of N-acetyl-l-cysteine on chronic heat stress-induced oxidative stress and inflammation in the ovaries of …
Dose: 1 g/kg NAC in basal diet
vs: Placebo
효과: None
None
Key Statistics
10
연구
1500
참여자
↑
Positive
B
등급
Referenced Papers
PloS one
2025
5 인용
Drugs in context
2025
1 인용
Journal of biomedical …
2025
Arthritis care & …
2023
36 인용
Poultry science
2023
13 인용
European review for …
2023
2 인용
Alcoholism, clinical and …
2022
4 인용
Journal of thermal …
2021
24 인용
N-acetyl-l-cysteine attenuates oxidative damage and neurodegeneration in rat brain during aging.
Other
Canadian journal of …
2018
37 인용
Natural product communications
2011
7 인용
Phytomedicine : international …
2008
100 인용
Cardiovascular research
2006
42 인용
Primary care
2002
56 인용
Polski merkuriusz lekarski …
2002
16 인용
Respirology (Carlton, Vic.)
1998
14 인용
Fortschritte der Medizin
1992
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 600-1,200 mg/day
- respiratorysupport:
- 600 mg 2-3x/day
상한량: No established UL; doses up to 1,800 mg/day widely studied
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| 20 mg/kg/day acute; 200 mg TID chronic | -- | Positive | -- |
| 0.2% supplementation | 8 weeks | Positive | 270 |
| None | -- | Positive | -- |
| Cannabidiol (CBD) | -- | Mixed | -- |
| 600 mg | 1.0 weeks | Mixed | 333 |
| 1 g/kg NAC in basal diet | 3 weeks | Positive | 120 |
| None | -- | Mixed | -- |
| 1000 mg/kg in basal diet | 3 weeks | Positive | 120 |
권장 복용 시간: Between meals on empty stomach for optimal absorption
Safety & Side Effects
보고된 부작용
- ⚠ Gastrointestinal discomfort (nausea, diarrhea)
- ⚠ Unpleasant sulfur taste/smell
- ⚠ Headache
- ⚠ Rare: bronchospasm (in asthma patients, inhaled form)
알려진 상호작용
- ● Nitroglycerin (may enhance vasodilatory and headache effects)
- ● Activated charcoal (reduces NAC absorption)
- ● Anticoagulants (theoretical effect on platelet function)
일일 최대 섭취 허용량: No established UL; doses up to 1,800 mg/day widely studied
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does 퀘르세틴 help with 급성 기관지염?
Based on 10 studies with 1,500 participants, there is moderate evidence from clinical studies that 퀘르세틴 may support 급성 기관지염 management. Our evidence grade is B (Good Evidence).
How much 퀘르세틴 should I take for 급성 기관지염?
Studies have used various dosages. A commonly studied range is 600-1,200 mg/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 퀘르세틴?
Reported side effects may include Gastrointestinal discomfort (nausea, diarrhea), Unpleasant sulfur taste/smell, Headache, Rare: bronchospasm (in asthma patients, inhaled form). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 퀘르세틴 and 급성 기관지염?
We rate the evidence as Grade B (Good Evidence). This rating is based on 10 peer-reviewed studies with 1,500 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: 급성 기관지염
퀘르세틴 다른 건강 상태에 대한 근거
References
- [1] Shafaq Fatima. PLoS One. 2025. N-acetyl-L-cysteine and lauric acid; effective antioxidant and antimicrobial feed additives for juvenile Pacific white shrimp (Litopenaeus vannamei) cultured at high … doi:10.1371/journal.pone.0315819 PubMed
- [2] Francesca Benedetti et al.. Drugs Context. 2025. N-acetylcysteine in paediatrics: a review of efficacy, safety and dosing strategies in respiratory care. doi:10.7573/dic.2025-7-7 PubMed
- [3] Gege Yuan et al.. J Biomed Res. 2025. Improving in vitro induction efficiency of human primordial germ cell-like cells using N2B27 or NAC-based medium. doi:10.7555/JBR.38.20240433 PubMed
- [4] Mary-Ann Fitzcharles et al.. Arthritis Care Res (Hoboken). 2023. Cautious Hope for Cannabidiol (CBD) in Rheumatology Care. doi:10.1002/acr.24176 PubMed
- [5] Xianhong Cao et al.. Poult Sci. 2023. Effects of N-acetyl-l-cysteine on chronic heat stress-induced oxidative stress and inflammation in the ovaries of growing pullets. doi:10.1016/j.psj.2022.102274 PubMed
- [6] W Tang et al.. Eur Rev Med Pharmacol Sci. 2023. Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion. doi:10.26355/eurrev_202306_32628 PubMed
- [7] Matthew F McLaughlin et al.. Alcohol Clin Exp Res. 2022. Correlates of high phosphatidylethanol (PEth) levels and their concordance with self-reported heavy alcohol consumption among men who have sex with … doi:10.1111/acer.14891 PubMed
- [8] Yulan Zhao et al.. J Therm Biol. 2021. Effects of N-acetyl-l-cysteine on heat stress-induced oxidative stress and inflammation in the hypothalamus of hens. doi:10.1016/j.jtherbio.2021.102927 PubMed
- [9] Geetika Garg et al.. Can J Physiol Pharmacol. 2018. N-acetyl-l-cysteine attenuates oxidative damage and neurodegeneration in rat brain during aging. doi:10.1139/cjpp-2018-0209 PubMed
- [10] Jie Ma et al.. Nat Prod Commun. 2011. Simultaneous quantification of Echinacea species, Flos Lonicerae, Radix Scutellaria and Fructus Forsythiae combinations by rapid resolution liquid chromatography. PubMed
- [11] Taofikat B Agbabiaka et al.. Phytomedicine. 2008. Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis. doi:10.1016/j.phymed.2007.11.023 PubMed
- [12] Yao Sun et al.. Cardiovasc Res. 2006. Oxidative stress in aldosteronism. doi:10.1016/j.cardiores.2006.03.007 PubMed
- [13] Raja Jaber. Prim Care. 2002. Respiratory and allergic diseases: from upper respiratory tract infections to asthma. doi:10.1016/s0095-4543(01)00008-2 PubMed
- [14] Maciej Kupczyk et al.. Pol Merkur Lekarski. 2002. [Mucolytics in acute and chronic respiratory tract disorders. II. Uses for treatment and antioxidant properties]. PubMed
- [15] P Soepandi et al.. Respirology. 1998. The pattern of micro-organisms and the efficacy of new macrolide in acute lower respiratory tract infections. doi:10.1111/j.1440-1843.1998.tb00108.x PubMed
- [16] K P Völkl et al.. Fortschr Med. 1992. [Therapy of respiratory tract diseases with N-acetylcysteine. An open therapeutic observation study of 2,512 patients]. PubMed
- [17] H H Gerards et al.. Fortschr Med. 1991. [Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients]. PubMed
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.